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Abstract: The plasma protein binding (PPB) data of twelve antipsychotics (aripiprazole, clozapine, olanzapine, quetiapine, 
risperidone, sertindole, ziprasidone, chlorpromazine, flupentixol, fluphenazine, haloperidol, zuclopenthixol) were estimated 
using computed molecular descriptors, which included the electronic descriptor – polar surface area (PSA), the constitu-
tional parameter – molecular weight (Mw), the geometric descriptor – volume value (Vol), the lipophilicity descriptor (logP) 
and aqueous solubility data (logS), and the acidity descriptor (pKa). The relationships between computed molecular proper-
ties of the selected antipsychotics and their PPB data were investigated by simple linear regression analysis. Low correlations 
were obtained between the PPB data of the antipsychotics and PSA, Mw, Vol, pKa, logS (R <0.30) values, while relatively 
higher correlations (0.35<R2<0.70) were obtained for the majority of logP values. Multiple linear regression (MLR) analysis 
was applied to access reliable correlations of the PPB data of the antipsychotics and the computed molecular descriptors. 
Relationships with acceptable probability values (P<0.05) were established for five lipophilicity descriptors (logP values) 
with application of the acidity descriptor (pKa) as independent variables: AlogP (R2=0.705), XlogP3 (R2=0.679), ClogP 
(R2=0.590), XlogP2 (R2=0.567), as well as for the experimental lipophilicity parameter, logPexp (R2=0.635). The best correla-
tions obtained in MLR using AlogP and pKa as independent variables were checked using three additional antipsychotics: 
loxapine, sulpiride and amisulpride, with the PPB values of 97%, “less than” 40% and 17%, respectively. Their predicted 
PPB values were relatively close to the literature data. The proposed technique confirmed that lipophilicity, together with 
acidity significantly influences the PPB of antipsychotics. The described procedure can be regarded as an additional in vitro 
approach to the modeling of the investigated group of drugs.
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INTRODUCTION
Psychotic illnesses can be categorized into several 
mental disorders such as psychoses, neuroses and 
mood disorders. Antipsychotic drugs, which are his-
torically known as antischizophrenic or neuroleptic 
drugs, are traditionally used in schizophrenia treat-
ment [1-5]. Today, there are many antipsychotic drugs 
and new medical entities are continuously introduced 
into clinical practice. They can be classified into two 
main groups: the first group contains originally devel-
oped drugs. These are antipsychotics of the first gen-
eration. This group is known as typical antipsychotics 
[1-5]. The other group represents newly developed 
antipsychotics, which are are known as atypical or 
antipsychotics of the second generation [1-5]. 
Considering their mechanism of action, antipsy-
chotic drugs are mostly dopamine receptor antago-
nists. However, they can affect other targets, including 
cholinergic, α adrenergic, histamine or serotonin recep-
tors, which can increase their medical efficacy. With 
the aim of improving the quality of life of millions of 
patients, changes in the modes of application as well 
as the introduction of newly synthesized antipsychotic 
drugs has significantly increased in recent years [1-5].
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The medical success or failure of drugs, their ther-
apeutic effect, as well as side effects, are influenced 
by their pharmacokinetic properties, the absorption, 
distribution, metabolism, route of elimination (ADME 
criteria). Furthermore, a drug’s in vivo efficiency is 
significantly influenced by its plasma protein binding 
(PPB). Once we understand these pharmacokinetic 
processes and include the obtained knowledge in the 
design and synthesis of new drugs, we will be able to 
significantly increase the drugs’ therapeutic success 
and reduce their unwanted effects [6,7].
The physicochemical properties of molecules exert 
a considerable influence on the ADME properties of 
drugs. The molecular weight and volume, lipophilic-
ity as well as solubility, followed by polar surface area 
(PSA) and acidity, significantly affect the drugs’ absorp-
tion, distribution and penetration into tissues, PPB and 
route of elimination [8-11]. If more lipophilic molecules 
are to be compared with less lipophilic ones with simi-
lar properties, they will mostly show higher degrees 
of absorption and PPB, as well as better penetration 
into tissues and distribution. On the other hand, less 
lipophilic drugs are mostly eliminated in the urine, 
while highly lipophilic ones usually exhibit high de-
grees of fecal elimination. The lipophilicity effects agree 
with Lipinski’s “rule of 5” [12]. This rule predicts that 
low absorption or permeation of a drug is more likely 
when the calculated lipophilicity descriptor is found 
to be greater than 5, and when the molecular weight is 
greater than 500, as well as when there are more than 5 
hydrogen-bond donors and 10 hydrogen-bond accep-
tors in a drug molecule [12].
Many authors have studied this group of drugs. 
From the early years of their discovery and develop-
ment to the present day, the design and synthesis, 
pharmacokinetics, pharmacodynamics and efficacy 
of antipsychotics have been examined [4,5,13-15]. 
In our previous research, we studied the relation-
ships between PPB data (also including absorption 
and elimination) of selected antihypertensive drugs 
and their computed molecular descriptors, and estab-
lished suitable models [16-21]. The aim of the present 
study was to evaluate the relationships between the 
PPB data of twelve selected antipsychotics and their 
computed molecular properties. By application of 
MLR, molecular descriptors which are most appro-
priate for estimating the antipsychotics’ PPB were 
identified, and in the final stage of study, the best 
established model was checked on three additional 
drugs, loxapine, sulpiride and amisulpride.
MATERIALS AND METHODS
Calculation of the molecular descriptors and 
statistical analysis
Calculation of antipsychotics’ molecular descriptors 
based on their molecular structures was performed 
using several software packages. The descriptors PSA, 
Mw and Vol were calculated with Molinspiration De-
piction Software (www.molinspiration.com). The li-
pophilicity descriptors, seven different logP values 
(AlogPs, AClogP, milogP, AlogP, MlogP, XLOGP2, 
XLOGP3), and their aqueous solubility data (logS), 
were calculated using the software package Virtual 
Computational Chemistry Laboratory (www.vcclab.
org). The calculation of another lipophilicity param-
eter, ClogP values, was performed with the Chem-
Draw ultra 12.0 software package. DrugBank (www.
drugbank.ca) was used for calculation of the acidity 
descriptors (pKa values). The PPB data, as well as val-
ues of the experimental lipophilicity parameters (log-
Pexp) of the investigated drugs, were obtained using 
the DrugBank (www.drugbank.ca). Microsoft Excel 
2003 was used for statistical analysis.
RESULTS AND DISCUSSION
For all investigated antipsychotics (Tables 1 and 2), dif-
ferent molecular descriptors (Table 3) were obtained. 
According to the available data, the selected drugs 
mostly have high and relatively similar values of PPB, 
ranging from 77% for risperidone to 99% for sertin-
dole, ziprasidone, fluphenazine, zuclopenthixol, 100% 
for aripiprazole (Table 4) and 97%, <40% and 17%, for 
loxapine, sulpiride and amisulpride, respectively. In the 
preliminary investigation, the relationships between 
the drug PPB and all calculated molecular descriptors 
were investigated using simple linear regression. Low 
correlations with R2<0.30 were obtained between the 
PPB values and the values of PSA, Mw, Vol, pKa and 
logS, while relatively higher correlations (0.35<R2<0.70) 
were obtained for the majority of logP values.
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In the next stage of the study, relationships be-
tween the PPB and two different molecular descriptors 
were investigated by MLR. When the experimental 
lipophilicity parameters and additional molecular de-
scriptors, Mw, Vol and pKa as independent variables, 
were used for PPB estimation, a relationship with an 
acceptable probability value of P<0.05 and R2=0.635 
was established only for logPexp values with the acid-
ity descriptors (pKa) as the second variable (Eq. 1). 
Eq.1:
PPBpred (%)=6.158(±1.804) logPexp–6.064(±2.581) 
pKa+118.263(±18.097),
with n=10; R2=0.635; S.D.=5.041; F=6.103.
Relationships with acceptable probability val-
ues (P<0.05) were established for the calculated li-
pophilicity descriptors, AlogP, XlogP3, ClogP and 
XlogP2, with application of pKa as follows: R2=0.705; 
R2= 0.679; R2=0.590 and R2=0.567, respectively. The 
obtained correlations are presented by the following 
equations: Eq. 2; Eq. 3; Eq. 4; Eq. 5. 
Eq.2:
PPBpred(%)=9.904(±2.138) AlogP-4.165(1.936) 
pKa+83.358(±14.425),
where n=12; R2=0.705; S.D.=4.212; F=10.766;
Eq.3:
PPBpred(%)=7.178(±1.649) XlogP3- 5.108(±2.128) 
pKa+108.207(±15.002),
where n=12; R2=0.677; S.D.=4.398; F=9.502;
Eq.4:
PPBpred (%)=7.330(±2,040) ClogP-4.598(±2.275) 
pKa+100.816(±16.753),
where n=12; R2=0.590; S.D.=4.966; F=6.484.
Table 1. The structures of the investigated antipsychotics.
*ChemDraw ultra 12.0 software package
Table 2. The structures of loxapine, sulpiride and amisulpride.
*Chemdraw ultra 12.0 software package
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Eq.5:
PPBpred (%)=8.434(±2.460) XlogP2-5.267(±2.553) 
pKa+104.196(±17.285)
where n=12; R2=0.567; S.D.=5.102; F=5.905.
The presented correlations can be considered 
as good [22]. The values of the antipsychotics’ PPB 
predicted using the presented equations are shown 
in Table 4. 
The ADME properties [23] and their PPB influ-
ence the in vivo efficacy of drugs. The main plasma-
binding proteins are albumin, α1-acid glycoprotein and 
lipoproteins. Drug molecules in vivo may be bound 
to proteins and lipids in the plasma, to proteins and 
lipids in tissues, or they can be free and diffuse in the 
aqueous environment of the blood and tissues [24-26]. 
The degree of drug afﬁnity for plasma proteins consid-
erably influences their distribution in target tissue, ef-
fectiveness, duration of action, elimination, and their 
therapeutic and side effects. Therefore, the estimation 
of drug PPB is of great importance for comprehend-
ing their pharmacokinetics and pharmacodynamics 
[24-26]. The collected descriptors play important 
roles in drug absorption, distribution, metabolism, 
elimination and PPB, with lipophilicity as one of the 
most important molecular properties that is respon-
sible for a drug’s increased absorption, penetration 
into tissues, higher degree of distribution and higher 
degree of PPB [9-12]. Several lipophilicity descriptors 
(AlogPs, AClogP, milogP, AlogP, MlogP, XLOGP2, 
XLOGP3, ClogP and logPexp) were obtained for the 
investigated group of drugs using several software 
packages that include different calculation methods. 
The differences between these methods resulted in 
distinctions between absolute logP values [27]. 
Regarding the importance of physicochemical 
properties, the relationships between the PPB and all 
calculated molecular descriptors were investigated by 
simple linear regression. Low correlations (R2<0.30) 
were obtained between the PPB data and PSA, Mw, 
Vol, pKa and logS data, while relatively higher cor-
relations were obtained for the logP values. The best 
correlations were obtained for the following param-
eters: AlogPs (R2 =0.69), AlogP (R2 =0.55), milogP (R2 
=0.49), XlogP3 (R2 =0.47) and ClogP (R2 =0.42). For 
XlogP2 and logPexp values, the coefficients R2 were 
0.36 and 0.35, respectively, while AClogP and MlogP 
provided correlations with R2<0.20.
Using MLR, all collected lipophilicity descriptors 
were tested as the first independent variable. Mw, Vol 
and pKa were chosen as the second independent vari-
able values, while the values of PSA and logS could not 
be used since their relationships with logP provided 
correlations with R2>0.30. It was observed that two 
lipophilicity parameters, MlogP and AClogP, were ex-
ceptions since they could not be used with pKa as the 
second independent variable since their correlation 
with R2 was about 0.50. Moreover, these two lipophilic-
ity descriptors with additional molecular descriptors, 
Mw and Vol, provided low correlations with R2<0.40.
Table 3. Molecular descriptors of antipsychotics.
No pKa Mw Vol logPexp* ClogP AlogP XLOGP2 XLOGP3
1. 7.46 448 395 4.50 4.63 5.00 4.49 4.64
2. 7.50 327 292 3.23 4.10 3.95 3.74 3.08
3. 7.24 312 286 2.00 3.40 3.21 2.32 2.86
4. 7.06 384 352 2.80 3.37 3.18 2.83 2.14
5. 8.76 410 374 2.50 2.71 3.32 3.07 2.72
6. 8.59 441 390 NA** 5.07 4.68 4.10 4.07
7. 7.09 413 352 3.80 3.58 4.26 3.77 4.02
8. 9.20 319 285 5.41 5.80 4.74 4.92 5.19
9. 8.51 435 379 4.51 4.34 4.82 4.42 4.51
10. 8.21 438 381 4.36 4.62 4.44 4.16 4.36
11. 8.05 376 337 4.30 3.85 3.89 3.98 3.23
12. 8.43 401 361 NA 4.13 4.54 4.12 4.31
Numbers denote the investigated antipsychotics as indicated in Table 1. 
*Drug Bank: www.drugbank.ca. 
**NA – not available.
Table 4. Drug PPB data (*) collected using the software pack-
age Drug Bank and values predicted using (1) logPexp and pKa; 
(2) AlogP and pKa; (3) XlogP3 and pKa; (4) ClogP and pKa; (5) 
XlogP2 and pKa.
PPB (*) PPB (1) PPB (2) PPB (3) PPB (4) PPB (5)
1. 100 101 105 103 100 103
2. 97 93 94 92 96 96
3. 93 87 88 92 92 86
4. 83 93 88 88 93 91
5. 77 81 83 83 80 84
6. 100 NA** 97 94 98 94
7. 99 99 99 101 94 99
8. 95 96 95 98 101 97
9. 95 94 99 97 93 97
10. 99 95 96 98 97 96
11. 95 96 91 90 92 95
12. 99 NA 96 96 92 95
The numbers denote the investigated drugs as indicated in 
Table 1. 
**NA (logPexp was not available).
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Application of other seven lipophilicity descriptors 
(logPexp and 6 calculated descriptors, AlogPs, milogP, 
AlogP, XLOGP2, XLOGP3 and ClogP), with the addi-
tional molecular descriptors (molecular weight, volume 
or acidity as independent variables) in MLR provided 
correlations with R2>0.55. However, using MLR, the re-
lationships with acceptable probability values (P<0.05) 
were established for the experimental lipophilicity pa-
rameter, logPexp (R2=0.635), as well as for four calcu-
lated lipophilicity descriptors (logP values) with the 
application of the acidity descriptor, pKa, as the sec-
ond independent variable; AlogP (R2=0.705), XlogP3 
(R2=0.679), ClogP (R2=0.590), XlogP2 (R2=0.567) was 
noted. All obtained correlations can be considered as 
good, with acceptable P values [22].
The best established correlations were obtained 
with Eq.1; Eq.2 and Eq.3 by MLR analysis with log-
Pexp, AlogP or XlogP3 and pKa as independent vari-
ables, and are presented in Figs. 1 and 2. The rela-
tionships between the degree of PPB obtained with 
the software package Drug Bank and those predicted 
using logPexp and pKa are presented in Fig. 1. Since 
for sertindole and zuclopenthixol the values of log-
Pexp were not available [24], their PPB values could 
not be predicted using Eq.1 and consequently they are 
not presented on Fig 1.
The relationships between PPB obtained with the 
software package [24] and those predicted using AlogP 
or XlogP3 and pKa as independent variables are pre-
sented in Fig 2. The best established correlation (Eq.2) 
obtained using AlogP and pKa as independent vari-
ables was checked using three additional antipsychot-
ics: the typical antipsychotic loxapine and two atypical 
antipsychotics, sulpiride and amisulpride. Their PPB 
values in the literature are 97%, <40% and 17%, respec-
tively. These values were out of the 77%-100% range 
where the values for PPB modelling belong. Their pKa 
values were 7.18, 9.12 and 9.37, respectively [24]. The 
values of their lipophilicity parameter AlogP, which 
provided the best model (Eq.2), were 3.96; 0.83 and 
1.13, respectively [23]. The correlation presented can 
be considered as suitable for PPB prediction of antip-
sychotics since the predicted PPB values were relatively 
close to the literature data for loxapine (93%), sulpiride 
(26%) and amisulpride (27%).
The correlations between antipsychotics’ PPBD 
and their molecular descriptors, lipophilicity param-
eters (logPexp, AlogP, XLOGP2, XLOGP3 and ClogP) 
and the acidity descriptor (pKa) as independent vari-
ables determined by MLR, confirmed that the pro-
posed in silico technique can be considered a high-
throughput screening approach for estimating PPB. 
Fig. 1. Relationships between PPB data of antipsychotics collected 
using the software package Drug Bank (Series 1) and values pre-
dicted using logPexp and pKa (Series 1). The numbers denote the 
investigated antipsychotics, as indicated in Table 1.
Fig. 2. Relationships between the PPB data data of antipsychotics 
collected using the software package Drug Bank (Series 1) and 
values predicted using AlogP and pKa (Series 2), and XlogP3 and 
pKa (Series 3). The numbers denote the investigated antipsychot-
ics, as indicated in Table 1.
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The important role of lipophilicity and acidity may be 
a consequence of drug interactions during transport 
to their biological targets and their interactions with 
their receptors. The proposed methodology, which 
established lipophilicity and acidity as essential for 
the PPB of antipsychotic drugs, can be considered as 
an innovative approach for investigating the degree 
of PPB of antipsychotic drugs.
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